AlphAIAlphAI — Financial news for AI agents
redditchstandard.co.ukSEP 161 min read$BIIB

BREAKING - Petition which could help FA sisters reaches 100,000 signatures

A petition for Friedreich’s ataxia treatment omaveloxolone (Skyclarys) reached 100,000 signatures. Biogen withdrew its evidence submission to NICE, halting the appraisal. NICE requires Biogen's participation to recommend the drug. Biogen plans to resubmit evidence when confident of approval.

Original reporting
redditchstandard.co.uk
Published Sep 16, 2026, 11:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 1:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BREAKING - Petition which could help FA sisters reaches 100,000 signatures — source image
Source · redditchstandard.co.uk
Decision brief

The 30-second read

$BIIBBearishLow
01

Why it matters

Biogen's withdrawal stalls UK market entry for omaveloxolone, a treatment for Friedreich’s ataxia.

02

Market read

Regulatory delay may weigh on Biogen's UK valuation but broader impact is limited.

03

What to watch

Biogen already has approvals in 12 European countries, which could mitigate UK loss.

Relevance 5/10Novelty 5/10Timing: current

Background

NICE is the UK body that assesses cost‑effectiveness of new medicines for NHS funding.

Company-level read

Ticker impact

$BIIBBearishMedium confidence
Context

Biogen withdrew its evidence submission for omaveloxolone from the NICE appraisal process.

Expected impact

Short-term downside pressure expected.

Evidence & confidence

Regulatory setback reduces near-term revenue prospects; market may react negatively.

Market effects

Sector

UK rare‑disease drug approvals face heightened scrutiny.

Regional

Potential modest impact on UK biotech sector.

Global

Limited; mainly affects Biogen and UK regulatory outlook.

Counterpoint

What could challenge this read

Biogen may use the delay to negotiate better pricing, leading to stronger long‑term positioning.

Key entities

  • Company
    Biogen

    Pharmaceutical developer of omaveloxolone (Skyclarys).

  • Regulatory Body
    NICE

    UK agency responsible for health technology assessments.

Read at source← All news

Related articles

SEP 19
$BIIBMedAI 8/10

BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study

Biogen Inc's (BIIB) stock fell 7% after presenting mixed mid-stage trial results for its Alzheimer's drug diranersen. The study showed positive signals, particularly for the 60 mg dose, but raised questions about dosing and consistency. RBC questioned the replicability of results, while Stifel maintained a 'Buy' rating. BIIB has a 12-month average price target of $224.45, up 7% from the last close.

stocktwits.com2 min
SEP 18
$BIIBHighAI 9/10

Eisai and Biogen announced Japan's approval of LEQEMBI Pen, a subcutaneous formulation of lecanemab for Alzheimer's treatment

Eisai and Biogen announced Japan's approval of LEQEMBI Pen, a subcutaneous formulation of lecanemab for Alzheimer's treatment. The autoinjector allows weekly at-home administration, reducing clinic visits and healthcare resource use. Approval was based on Phase 3 study data, showing similar efficacy and safety to IV administration. Eisai leads development, with both companies co-commercializing.

acnnewswire.com2 min
SEP 18
$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

rttnews.com3 min
SEP 17
$BIIBMedAI 8/10

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M

Biogen Inc. (BIIB) reported that EMPAVELI (pegcetacoplan) showed a 75% relative reduction in proteinuria in adolescents with C3G or primary IC-MPGN in a Phase 3 study. The FDA recently expanded EMPAVELI's label to include reducing kidney function loss in patients aged 12 and older. The drug is the only approved treatment for these conditions in adolescents, according to the company.

leaderpost.com2 min